Analyst Price Targets — VNDA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 11:09 am | — | H.C. Wainwright | $24.00 | $8.48 | TheFly | Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright |
| January 5, 2026 11:05 am | — | H.C. Wainwright | $22.00 | $8.25 | TheFly | Vanda Pharmaceuticals price target raised to $22 from $20 at H.C. Wainwright |
| December 31, 2025 10:04 am | — | Jefferies | $7.50 | $7.03 | TheFly | Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies |
| November 5, 2025 7:42 am | Madison El-Saadi | B.Riley Financial | $11.00 | $4.35 | StreetInsider | B.Riley Starts Vanda Pharmaceuticals (VNDA) at Buy |
| July 11, 2024 6:12 am | Charles Duncan | Cantor Fitzgerald | $11.00 | $5.21 | TheFly | Vanda Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald |
Latest News for VNDA
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 5,310,265 shares, a growth of 65.9% from the March 15th total of 3,200,424 shares. Based on an average daily volume of 2,225,454 shares,
Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Atrinsic (NASDAQ: PTIX - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Insider and Institutional Ownership 88.1% of Vanda Pharmaceuticals
WASHINGTON, April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification. The proposal would eliminate the simple statutory requirement that the FDA must review a new drug application (NDA) within 180 days of filing.
WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving glucagon-like peptide-1 (GLP-1) receptor agonist therapies. NEREUS™ was recently approved for the prevention of vomiting induced by motion.1 GLP-1 receptor agonists, including…
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.51 and traded as high as $7.04. Vanda Pharmaceuticals shares last traded at $6.97, with a volume of 768,496 shares traded. Wall Street Analysts Forecast Growth
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VNDA.
U.S. House Trading
No House trades found for VNDA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.